Curcumin Nanoemulsion as a Novel Chemical for the Treatment of Acute and Chronic Toxoplasmosis in Mice  

Sanaz Jafarpour Azami, Aref Teimouri, Hossein Keshavarz, Amir Amani, Fariba Esmaeili, Hamid Hasanpour, Samira Elikaee, Hamid Salehiniya, and Saeedeh Shojaee 

The aim of this research was to create a curcumin nanoemulsion (CR-NE) to address the  issues of weak water solubility and low bioavailability of CR, as well as to assess its efficacy in  treating acute and chronic toxoplasmosis in mouse models. For the first time, the current study’s  findings demonstrated the ability of CR-S and CR-NE in the treatment of acute and chronic toxoplasmosis in mouse models. CR-NE, on the other hand, was more effective than CR-S, and  it appears that CR-NE may be a promising formula for the treatment of acute and chronic  toxoplasmosis, especially in those with latent bradyzoites in the brain. Toxoplasma gondii is a  worldwide obligate intracellular protozoan that can infect almost all warm-blooded animals,  including humans. Humans are often affected by viable tissue cysts by consuming raw or  undercooked meats, or sporulated oocysts by eating contaminated vegetables or drinking  contaminated water. The current study’s findings indicate that CR-S and CR-NE have the ability  to treat acute and chronic toxoplasmosis in mice for the first time. It’s worth noting that toxoplasmosis treatment in immunocompromised patients is required; therefore, more testing of  curcumin nanoemulsion alone or in combination with other nanoparticles against reactivated  toxoplasmosis or interferon-gamma knockout murine models is recommended. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233476/